DH20931

DH20931 is a **novel small molecule biisoquinoline derivative** that acts as a **ceramide synthase 2 (CerS2) stimulator/agonist**[3][5]. It induces the synthesis of very long chain fatty acid (VLCFA) ceramides, resulting in lipotoxic and endoplasmic reticulum (ER) stress. This mechanism triggers the ATF4/CHOP/PUMA apoptotic pathway, leading to cancer cell death[1][3]. DH20931 has shown significant **growth inhibitory effects in both triple-negative and triple-positive human breast cancer cell lines**, with increased potency compared to structurally related noscapine[5]. It is being investigated primarily for breast cancer, specifically triple-negative breast cancer, by researchers at the University of Florida[3][5]. Research is ongoing to further understand its mechanism, resistance profile, safety, and side effects[3].

Other names

biisoquinoline derivative DH209311c6,6'-dimethoxy biisoquinoline imidazolium compound DH20931